pharma · Becker Muscular Dystrophy · Muscular Dystrophies · EWTX
Edgewise Therapeutics
Edgewise Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker EWTX. Primary therapeutic focus areas include Becker Muscular Dystrophy, Muscular Dystrophies, Hepatic Impairme
Company details
- Status
- Public
- HQ
- 1715 38th St., Boulder, CO 80301, US
- Founded
- 2017
- Employees
- 154
- Programs
- 15
- Drugs
- 3
- Patents
- 7
Quick answer
Edgewise Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker EWTX. Primary therapeutic focus areas include Becker Muscular Dystrophy, Muscular Dystrophies, Hepatic Impairment (HI), Hypertrophic Cardiomyopathy, Renal Impairments. NovaPharmaNews links 15 clinical program(s), 0 drug profile(s), and 7 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (10), phase 2 (5).
Company snapshot
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions.
- 15 active pipeline program(s) linked via ClinicalTrials.gov.
- 7 US patent(s) indexed to this assignee profile.
- 15 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Edgewise Therapeutics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- deal
Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal
Recent coverage
Edgewise Therapeutics’ EDG-7500 clears key Phase 2 test
Edgewise Therapeutics says EDG-7500 met a key Phase 2 test in obstructive hypertrophic cardiomyopathy. The evidence points to a cardiac sarcomere modulator still in clinical development, with CIRRUS-HCM as the named study.
Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal
French pharmaceutical giant Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for an upfront payment of $1.55 billion, with potential milestone payments reaching up to $2.7 billion. This strategic move significantly expands Servier's footprint in the rare disease and neurology space.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- Phase 2
Active clinical programs
- Phase 2
- Phase 2
- Phase 2
- Phase 2
Momentum
Proprietary activity score for Edgewise Therapeutics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Edgewise Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Edgewise Therapeutics?
-
Is Edgewise Therapeutics publicly traded?
-
What drugs does Edgewise Therapeutics develop or market?
-
What are the latest developments for Edgewise Therapeutics?
-
What therapeutic areas does Edgewise Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.